Preexposure prophylaxis for HIV prevention

New England Journal of Medicine

Volumn 367, Issue 5, 2012, Pages 462-465

  Abdool Karim, Salim S ^a,b   Gray, Glenda E ^c   Martinson, Neil ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NONSTEROID ANTIINFLAMMATORY AGENT; ADENINE; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ALLERGY; ARTICLE; CIRCUMCISION; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LOW BACK PAIN; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RISK ASSESSMENT; SAFE SEX; SEXUAL BEHAVIOR; SEXUAL COUNSELING; ADOLESCENT; CASE REPORT; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED;

ADENINE; ADOLESCENT; ANTI-RETROVIRAL AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; SAFE SEX;

EID: 84864511894     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMclde1207706     Document Type: Article

References (13)

1. Abdool Karim Q, Kharsany AB, Frohlich JA, et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 2011;40:922-30.
2. Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:669-77.
3. Gust DA, Wiegand RE, Kretsinger K, et al. Circumcision status and HIV infection among MSM: reanalysis of a Phase III HIV vaccine clinical trial. AIDS 2010;24:1135-43.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
5. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
6. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
7. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
8. Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012;54:1504-13.
9. The 2010 National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South Africa, 2010. Pretoria, South Africa: Department of Health, 2011.
10. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Pittsburgh: Microbicide Trials Network, September 28, 2011 (http://www.mtnstopshiv.org/node/3619).
11. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009;199:14-9.
12. Meyer-Rath G, Brennan A, Long L, et al. Total cost and potential cost savings of the national antiretroviral treatment (ART) programme in South Africa, 2010 to 2017. Presented at the XVIII International AIDS Conference, Vienna, July 18-23, 2010. abstract.
13. The Southern African HIV Clinicians Society. Guidance to clinicians experiencing tenofovir and abacavir drug shortages. Cape Town, South Africa: Treatment Action Campaign, March 29, 2012.